Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/13714

Title: Efficacy of daily intake of Lactobacillus casei Shirota on respiratory symptoms and influenza vaccination immune response: a randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents
Authors: van Puyenbroeck, Karolien
Hens, Niel
Coenen, Samuel
Michiels, Barbara
Beunckens, Caroline
Molenberghs, Geert
Van Royen, Paul
Verhoeven, Veronique
Issue Date: 2012
Citation: AMERICAN JOURNAL OF CLINICAL NUTRITION, 95 (5), p. 1165-1171
Abstract: Background: Age is associated with immune dysregulation, which results in an increased infection rate and reduced effectiveness of vaccination. Objective: We assessed whether an intervention with Lactobacillus easel Shirota (LcS) in elderly nursing home residents reduced their susceptibility to respiratory symptoms and improved their immune response to influenza vaccination. Design: Between October 2007 and April 2008, a randomized, double-blind, placebo-controlled trial was conducted in 737 healthy people aged >= 65 y in 53 nursing homes in Antwerp, Belgium. Volunteers were randomly assigned to receive a probiotic (n = 375; 2 bottles of fermented milk that contained >= 6.5 x 10(9) live LcS/bottle) or a placebo (n = 362; similar drink with no bacteria) for 176 d. After 21 d, all subjects received an influenza vaccination. Primary outcome parameters were the number of days with respiratory symptoms, the probability of respiratory symptoms, and antiinfluenza antibody titer by hemagglutination inhibition after vaccination. Results: Univariate and multivariate modeling showed no effect of the probiotic on clinical outcome parameters. Generalized linear mixed modeling showed no effect of the probiotic itself on the probability of respiratory symptoms [OR of probiotic: 0.8715; 95% CI: 0.6168. 1.2887). No significant difference regarding the influenza-vaccination immune response was shown. Conclusion: The results of this study show that daily consumption of a fermented milk drink that contains LcS has no statistically or clinically significant effect on the protection against respiratory symptoms. This trial was registered at clinicaltrials.gov as NCT00849277. Am J Clin Nutr 2012;95:1165-71.
Notes: [van Puyenbroeck, Karolien; Coenen, Samuel; Michiels, Barbara; Van Royen, Paul; Verhoeven, Veronique] Univ Antwerp, Dept Primary & Interdisciplinary Care, B-2610 Antwerp, Belgium. [Hens, Niel; Coenen, Samuel] Univ Antwerp, Vaccine & Infect Dis Inst, WHO Collaborating Ctr, B-2610 Antwerp, Belgium. [Hens, Niel] Univ Antwerp, Ctr Hlth Econ Res & Modeling Infect Dis, B-2610 Antwerp, Belgium. [Hens, Niel; Beunckens, Caroline; Molenberghs, Geert] Hasselt Univ, I BioStat, Diepenbeek, Belgium. [Hens, Niel; Beunckens, Caroline; Molenberghs, Geert] Katholieke Univ Leuven, Diepenbeek, Belgium. arolien.vanpuyenbroeck@ua.ac.be
URI: http://hdl.handle.net/1942/13714
DOI: 10.3945/ajcn.111.026831
ISI #: 000303140700022
ISSN: 0002-9165
Category: A1
Type: Journal Contribution
Validation: ecoom, 2013
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version209.98 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.